- Home
- ANGO vs RZLT Comparison
ANGO vs RZLT Comparison
Compare ANGO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- RZLT
- Stock Information
- Founded
- ANGO 1988
- RZLT 2010
- Country
- ANGO United States
- RZLT United States
- Employees
- ANGO N/A
- RZLT N/A
- Industry
- ANGO Medical/Dental Instruments
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- RZLT Health Care
- Exchange
- ANGO Nasdaq
- RZLT Nasdaq
- Market Cap
- ANGO 279.1M
- RZLT 292.0M
- IPO Year
- ANGO 2004
- RZLT N/A
- Fundamental
- Price
- ANGO $11.94
- RZLT $4.92
- Analyst Decision
- ANGO Strong Buy
- RZLT Strong Buy
- Analyst Count
- ANGO 3
- RZLT 8
- Target Price
- ANGO $13.00
- RZLT $11.63
- AVG Volume (30 Days)
- ANGO 849.3K
- RZLT 336.6K
- Earning Date
- ANGO 01-08-2025
- RZLT 02-11-2025
- Dividend Yield
- ANGO N/A
- RZLT N/A
- EPS Growth
- ANGO N/A
- RZLT N/A
- EPS
- ANGO N/A
- RZLT N/A
- Revenue
- ANGO $286,498,000.00
- RZLT N/A
- Revenue This Year
- ANGO N/A
- RZLT N/A
- Revenue Next Year
- ANGO $7.69
- RZLT N/A
- P/E Ratio
- ANGO N/A
- RZLT N/A
- Revenue Growth
- ANGO N/A
- RZLT N/A
- 52 Week Low
- ANGO $5.26
- RZLT $0.92
- 52 Week High
- ANGO $13.13
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- ANGO 64.64
- RZLT 50.84
- Support Level
- ANGO $11.65
- RZLT $4.47
- Resistance Level
- ANGO $12.96
- RZLT $4.98
- Average True Range (ATR)
- ANGO 0.69
- RZLT 0.32
- MACD
- ANGO 0.16
- RZLT -0.01
- Stochastic Oscillator
- ANGO 72.83
- RZLT 42.86
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.